Overview

Comparative Pharmacokinetic Trial of RGB-03 and MabThera

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Pharmacokinetic properties, efficacy, safety and tolerability of RGB-03 and MabThera will be compared in patients suffering from Rheumatoid Arthritis.

Phase:

Phase 1

Details

Lead Sponsor:

Gedeon Richter Plc.

Treatments:

Rituximab